News

SA biotech buys Birmingham company

CytoBioscience CEO James Garvin said the acquisition of BioDtech is a big win for his San Antonio-based ...

SA biotech CEO: Company on the verge of taking cancer-detection product to market

Seno Medical Instruments Inc. CEO Tom Umbel said the company is picking up momentum. GABE HERNANDEZ | ...

Events

BioMed SA Annual Breakfast Meeting

When: 7:30-9:30 AM Tuesday, December 18, 2018 Where: Omni Hotel, 9821 Colonnade Blvd. Join ...
News
Biotech firm completes study on skin wart treatment
February 20, 2014

By Mike W. Thomas, San Antonio Business Journal

Local biotech firm ViroXis Corp. is wrapping up a Phase 2 clinical study of its treatment for a virus that causes skin warts.

The final patient of the 183-person enrolled study has completed treatment and the results will be known once the data has been analyzed. ViroXis has developed a drug for treating the Human Papilloma Virus (HPV) using oils from the East Indian Sandalwood tree. The study is being funded by the proceeds of a $5 million Series B private offering.

ViroXis also announced plans to initiate a second Phase 2 clinical study in a new direction to test its effect on Molluscum contagiosum (MCV) in a pediatric population. MCV is a highly contagious pox virus skin infection for which there are currently no approved prescription treatments.

"ViroXis has quickly emerged as leader in the development of botanical drug products, a new and important group of drug candidates afforded a distinct approval process by the (Food and Drug Administration)," says Ian Clements, CEO of ViroXis.

 

Stay informed. Subscribe to BioMed SA news alerts.